Pediatric perspective on pharmacogenomics

Adam Stevens, Chiara De Leonibus, Daniel Hanson, Andrew Whatmore, Philip Murray, Rachelle Donn, Stefan Meyer, Pierre Chatelain, Peter Clayton

    Research output: Contribution to journalArticlepeer-review


    The advances in high-throughput genomic technologies have improved the understanding of disease pathophysiology and have allowed a better characterization of drug response and toxicity based on individual genetic make up. Pharmacogenomics is being recognized as a valid approach used to identify patients who are more likely to respond to medication, or those in whom there is a high probability of developing severe adverse drug reactions. An increasing number of pharmacogenomic studies are being published, most include only adults. A few studies have shown the impact of pharmacogenomics in pediatrics, highlighting a key difference between children and adults, which is the contribution of developmental changes to therapeutic responses across different age groups. This review focuses on pharmacogenomic research in pediatrics, providing examples from common pediatric conditions and emphasizing their developmental context. © Future Medicine Ltd.
    Original languageEnglish
    Pages (from-to)1889-1905
    Number of pages16
    Issue number15
    Publication statusPublished - Nov 2013


    • Adverse drug reactions
    • Pediatrics
    • Personalized medicine
    • Pharmacogenomics


    Dive into the research topics of 'Pediatric perspective on pharmacogenomics'. Together they form a unique fingerprint.

    Cite this